Owlet Inc. Reports Strong Revenue Growth in Q2 2025 Amidst Operating Losses
Owlet Inc. (NYSE: OWLT), a leader in infant health monitoring technology, has released its financial results for the second quarter of 2025, showing a substantial increase in revenue despite ongoing operating losses. The company's commitment to empowering parents through innovative health monitoring products continues to drive growth, highlighted by the performance of its latest offerings.
1. Overview of Financial Performance
For the three months ending June 30, 2025, Owlet reported revenues of $26.06 million, marking a 25.9% increase from $20.70 million in the same period last year. This growth is attributed to strong sales of the Dream Sock and Dream Duo products, as well as the successful launch of the Owlet360 subscription service in January 2025.
Revenue Growth and Product Sales
The rise in revenue can be significantly linked to the increased demand for Owlet's flagship products. The Dream Sock, which monitors an infant's heart rate and oxygen levels, and the Dream Duo, which combines this monitoring with a smart baby monitor, have captured the attention of parents seeking peace of mind. The Owlet360 subscription service, which offers enhanced monitoring features and personalized insights, has also contributed to revenue growth.
Cost of Revenues and Gross Margin
Owlet's cost of revenues for Q2 2025 rose by 21.4% to $12.68 million, driven by higher product sales. However, the company managed to improve its gross margin from 49.5% to 51.3% over the same period. This improvement is attributed to a favorable product mix, enhanced fixed cost absorption, and reduced direct product costs, despite some negative impacts from tariffs.
| Aug 2024 | Aug 2025 | |
|---|---|---|
Net Income | -10.44M | -49.28M |
Profit | -10.44M | -49.28M |
Net Income Continuing | -10.44M | -49.28M |
Income Tax Expense | 27K | 77K |
Pretax Income | -10.41M | -49.20M |
Non-operating Income | 8.53M | -32.38M |
Operating Income | -18.95M | -16.82M |
Revenue | 65.63M | 89.77M |
Other Operating Income | 78K | 0 |
Costs and Expenses | 84.66M | 106.5M |
Cost of Revenue | 35.63M | 42.55M |
Operating Expenses | 48.95M | 64.03M |
Research & Development | 9.41M | 11.75M |
Selling, General & Administrative | 39.53M | 52.27M |
2. Operating Expenses: A Mixed Bag
General and Administrative Expenses
General and administrative expenses increased by 14.9%, totaling $7.23 million for the quarter. This rise was primarily due to increased compensation expenses and a growing headcount. However, a reduction in stock-based compensation partially offset these increases.
Sales and Marketing Expenses
Sales and marketing expenses saw a modest increase of 12.1%, reaching $4.32 million. The increase reflects the company's ongoing efforts to expand its market presence and promote its innovative products.
Research and Development Investment
In a bid to enhance its product offerings, Owlet significantly ramped up its research and development expenses, which surged by 59.4% to $3.75 million. This increase reflects the company's commitment to innovation and the development of new technologies to improve infant health monitoring.
3. Net Income and Expenses
Despite the impressive revenue growth, Owlet reported a net loss of $37.64 million for Q2 2025, a significant increase from a loss of $1.14 million in the same quarter of the previous year. The loss was primarily driven by a substantial increase in non-operating expenses, including a notable loss attributed to common stock warrants.
Interest and Other Expenses
Net interest expense skyrocketed from $20,000 in Q2 2024 to $979,000 in Q2 2025, reflecting the impact of the company's new debt arrangements. Additionally, the company recognized a loss of $34.75 million related to changes in the fair value of common stock warrants.
| Aug 2024 | Aug 2025 | |
|---|---|---|
Total Assets | 45.89M | 63.54M |
Total Current Assets | 42.53M | 60.74M |
Cash and Equivalents | 15.36M | 21.82M |
Net Inventories | 8.10M | 11.37M |
Accounts Receivable | 16.89M | 24.37M |
Restricted Cash and Investments | 0 | 300K |
Prepaid Expenses | 2.17M | 2.86M |
Total Non-current Assets | 3.36M | 2.8M |
Intangible Assets | 2.22M | 976K |
Net PP&E | 193K | 186K |
Lease Assets | 217K | 96K |
Other Non-current Assets | 731K | 1.54M |
Total Liabilities and Equity | 45.89M | 63.54M |
Temporary Equity and Redeemable Non-controlling Interest | 12.59M | 14.67M |
Total Liabilities | 66.72M | 108.0M |
Total Current Liabilities | 42.15M | 52.79M |
Accounts Payable and Accrued Liabilities | 29.06M | 33.88M |
Current Debt | 2.11M | 2.28M |
Current Deferred Revenue | 1.24M | 1.75M |
Other Current Liabilities | 9.73M | 14.87M |
Total Non-current Liabilities | 24.57M | 55.22M |
Long-term Debt | 0 | 3.38M |
Other Non-current Liabilities | 24.57M | 51.84M |
Total Equity and Non-controlling Interests | -33.42M | -59.15M |
Total Equity | -33.42M | -59.15M |
4. Liquidity and Capital Resources
As of June 30, 2025, Owlet has cash and cash equivalents of $21.83 million. The company has been proactive in securing its financial position by entering into various financing agreements, including a term loan facility and an asset-based revolving credit facility. However, the company faces ongoing challenges related to its accumulated deficit of $302.8 million and negative cash flows from operations.
Cash Flow Analysis
For the first half of 2025, Owlet experienced net cash used in operating activities of $8.17 million, an increase from $6.72 million in the previous year. Investing activities accounted for $199,000 in expenditures, primarily related to the development of a new subscription application. Financing activities generated $9.87 million, mainly driven by short-term borrowings and proceeds from warrant exercises.
| Aug 2024 | Aug 2025 | |
|---|---|---|
Net Change in Cash | -9.38M | 6.76M |
Net Cash from Operating Activities | -13.44M | -12.70M |
Operating Profit | -10.44M | -49.28M |
Adjustment to Operating Profit | -3.00M | 36.58M |
Net Cash from Investing Activities | -161K | -839K |
Productive Assets | 161K | 839K |
Net Cash from Financing Activities | 4.22M | 20.30M |
Debt | -3.53M | 3.30M |
Equity Issuance/Repurchase | 7.55M | 13.26M |
Other Financing Activities | 205K | 3.74M |
5. Conclusion: Future Outlook and Challenges
While Owlet's Q2 2025 results demonstrate robust revenue growth and a commitment to innovation, the company must address its operating losses and navigate the challenges of negative cash flows. With a growing product portfolio and a solid market strategy, Owlet aims to strengthen its financial position and continue delivering valuable health monitoring solutions to parents.
As the company moves forward, investors will be keenly watching its ability to convert revenue growth into profitability and manage its financial obligations effectively. The future remains bright for Owlet, provided it can sustain its growth trajectory while addressing its financial challenges.
